Limosilactobacillus reuteri ATCC PTA 5289 and DSM 17938 as adjuvants to improve evolution of pharyngitis/tonsillitis in children: randomised controlled trial

Abstract

Pharyngitis and tonsillitis are the most common acute respiratory infections (ARIs) in children aged ≤5 years. The analysis of published data showed that some probiotics could decrease the frequency and number of days with ARIs. This study evaluated the safety and efficacy of Limosilactobacillus reuteri ATCC PTA 5289 and DSM 17938 to reduce the duration and severity of ARI symptoms. This randomised controlled trial included children aged from 6 months to 5 years, with pharyngitis or tonsillitis, who were randomised to receive a probiotic product containing L. reuteri ATCC PTA 5289 and L. reuteri DSM 17938 or placebo, as drops, ingested orally for 10 days as adjuvants to the use of non-steroidal anti-inflammatory drugs. The main outcomes were the duration and severity of ARI symptoms. The secondary outcomes were changes in salivary immunoglobulin A and inflammatory biomarkers. There was no fever on day 2 and subsequent days in the L. reuteri group (37.3 ±0.5 °C vs 38.6±0.3 °C, P<0.05). Beginning on day 3, the severity of sore throat (5±0.9 vs 8±1.2, P<0.05) was lower in the L. reuteri group. Significant differences in the days with runny nose, nasal congestion, days of non-programmed visits to the medical office or emergency department, levels in tumoral necrosis factor-alpha (TNF-alpha) and related costs of treatment were observed in the L. reuteri group. The frequency of adverse events was similar between the groups. Therefore, L. reuteri ATCC PTA 5289 combined with L. reuteri DSM 17938 is a safe and effective adjunct to reduce the symptoms of pharyngitis or tonsillitis in children.

Missing Piece Study protocol: prospective surveillance to determine the epidemiology of group A streptococcal pharyngitis and impetigo in remote Western Australia

“…In addition, an evaluation of immune responses to these infections will supplement the burden of GAS infection data in our study cohort. The application of novel microbiome analysis will have implications for the development of probiotic therapeutics43 as an alternative to antibiotic therapy, and may assist in identifying children at high risk of GAS pharyngitis. Lastly, data on GAS transmission in our surveillance study will inform evidence-based environmental health practices to reduce transmission among children attending schools in remote regions.…”

A systematic review and meta‐analysis on nutritional and dietary interventions for the treatment of acute respiratory infection in pediatric patients: An EAACI taskforce

“…After literature screening, 50 articles published between 1996 and 2022 were retained for the systematic review. The studies were conducted in the following continents: 33 in Asia, 22,26,27,29,[31][32][33][35][36][37][38][39][40][41]43,45,[47][48][49][50][51][52][53][54][57][58][59][60][61][62][65][66][67] eight in Africa, 23,25,34,42,44,55,63,68 five in South America, 20,21,24,28,46 two in North America, 56,64 one in Central America, 19 and one in Oceania. 30 Four trials were conducted ...…”

Genomic, phenotypic, and clinical safety of Limosilactobacillus reuteri ATCC PTA 4659

“…Other well studied strains include American Type Culture Collection (ATCC) PTA 5289 (Lr5289), ATCC PTA 6475 (Lr6475), and ATCC PTA 4659 (Lr4659). Lr5289 has, together with DSM 17938, been described to ameliorate both oral cavity disorders and upper respiratory tract infections (Maya-Barrios et al., 2021 ; Schlagenhauf et al., 2020 ). Lr6475 has been shown to reduce bone loss (Nilsson et al., 2018 ) and, together with DSM 17938, to reduce antibiotic-associated side effects during treatment of Helicobacter pylori infections (Francavilla et al., 2014 ).…”